Merck Santé S.A.S.

Merck Santé S.A.S., a pharmaceutical preparation manufacturing company based in France, reported a total of approximately 1.84 billion kg CO2e in emissions for the year 2021. This total is comprised of about 1.52 billion kg CO2e in Scope 1 emissions and approximately 321 million kg CO2e in Scope 2 emissions. Scope 3 emissions for 2021 were approximately 4.01 billion kg CO2e, with purchased goods and services being the largest contributor at approximately 3.57 billion kg CO2e, followed by the use of sold products at about 1.21 billion kg CO2e.

In 2020, Merck Santé S.A.S. recorded total emissions of approximately 2.03 billion kg CO2e. This included around 1.71 billion kg CO2e for Scope 1 and approximately 322 million kg CO2e for Scope 2. Scope 3 emissions for 2020 amounted to approximately 3.82 billion kg CO2e, with purchased goods and services accounting for about 3.04 billion kg CO2e.

For 2019, the company reported total emissions of approximately 621 million kg CO2e, with Scope 1 at about 341 million kg CO2e and Scope 2 at approximately 280 million kg CO2e. Scope 3 emissions for 2019 were approximately 1.91 billion kg CO2e, with purchased goods and services data being missing for this reporting period. In 2018, total emissions were approximately 636 million kg CO2e, with Scope 1 at around 332 million kg CO2e and Scope 2 at approximately 304 million kg CO2e. Similar to 2019, purchased goods and services data was missing for Scope 3 in 2018.

Merck Santé S.A.S.'s climate commitments are cascaded from its parent organisation, Merck KGaA. Merck KGaA has set a near-term target to reduce avoidable Scope 1 emissions related to energy consumption and Scope 2 market-based emissions to zero by 2030. Furthermore, Merck KGaA has a long-term ambition to achieve net-zero greenhouse gas emissions by 2045, with specific targets for Scope 1 and Scope 2 emissions.